Arvinas, Inc. (ARVN) États Financiers et Données Historiques

Arvinas, Inc. (ARVN) — Prix $8.16 HealthcareBiotechnology — NASDAQ

Derniers résultats publiés:

États financiers détaillés de Arvinas, Inc. (ARVN): compte de résultat, bilan et tableau de flux de trésorerie. Suivez l'évolution des marges, de la dette, de la liquidité et de la rentabilité d'une année sur l'autre avec jusqu'à 20 ans d'historique.

Résumé de l'Analyse

Arvinas, Inc. a enregistré un chiffre d'affaires de $262.6M sur le dernier exercice, avec un CAGR sur 5 ans de 58.9%.

Marges des 12 derniers mois: marge brute 96.4%, marge opérationnelle -4.5%, marge nette 2.9%.

Au prix actuel de $8.16, ARVN se négocie à un PER de 39.84 et un ROE de 1.91%. La capitalisation boursière s'établit à $526M.

Compte de Résultat (10 ans)

Année2016201720182019202020212022202320242025
Revenus$6.7M$7.6M$14.3M$43.0M$25.9M$53.6M$131.4M$78.5M$263.4M$262.6M
Coût des Ventes000000000$5.2M
Marge Brute$6.7M$7.6M$14.3M$43.0M$25.9M$53.6M$131.4M$78.5M$263.4M$257.4M
R&D$19.9M$28.8M$45.2M$67.2M$108.4M$180.4M$315.0M$379.7M$348.2M$282.9M
Frais Généraux$3.2M$3.5M$12.9M$27.3M$38.3M$61.6M$79.6M$100.3M$165.4M$89.4M
Charges Opérationnelles$23.1M$32.3M$58.1M$94.5M$146.7M$242.0M$394.6M$480.0M$513.6M$372.3M
Résultat Opérationnel-$16.5M-$24.8M-$43.8M-$51.5M-$120.8M-$188.4M-$263.2M-$401.5M-$250.2M-$114.9M
EBITDA-$13.9M-$23.7M-$40.7M-$68.0M-$117.6M-$184.9M-$253.4M-$359.7M-$191.7M-$75.3M
Charges d'Intérêt$67404$50357$57440$100000$65000$1000000000
Résultat Avant Impôts-$14.4M-$24.0M-$41.5M-$70.3M-$119.3M-$191.0M-$261.6M-$366.4M-$198.3M-$80.5M
Impôts-$8740800000$20.9M$900000$600000$300000
Résultat Net-$14.4M-$24.0M-$41.5M-$70.3M-$119.3M-$191.0M-$282.5M-$367.3M-$198.9M-$80.8M
BPA$-7.56$-1.38$-1.31$-1.89$-3.02$-3.82$-5.31$-6.62$-2.77$-1.28
BPA Dilué$-7.56$-1.38$-1.31$-1.89$-3.02$-3.82$-5.31$-6.62$-2.77$-1.28
Actions en Circulation (Diluées)$1.9M$20.7M$31.6M$32.9M$39.5M$50.0M$53.2M$55.5M$71.9M$64.9M

Compte de Résultat (Trimestriel)

Année2025-Q32025-Q42026-Q12026-Q2
Revenus$41.9M$9.5M$15.6M$249.7M
Marge Brute$41.9M$8.3M$14.5M$240.7M
Résultat Opérationnel-$43.8M-$71.7M-$62.7M$164.1M
EBITDA-$34.0M-$66.0M-$56.4M$159.3M
Résultat Net-$35.1M-$67.4M-$57.6M$169.4M
BPA$-0.48$-1.04$-0.90$2.61
BPA Dilué$-0.48$-1.04$-0.90$2.58

Bilan (10 ans)

Année2016201720182019202020212022202320242025
Trésorerie$5.1M$30.9M$3.2M$9.2M$588.4M$108.3M$81.3M$311.7M$100.5M$142.9M
Placements à Court Terme$30.5M$8.3M$184.6M$271.7M$100.2M$1.39B$1.12B$949.3M$938.9M$542.5M
Créances$1.4M$26.0M$5.0M$6.3M$8.4M$25.7M$8.0M$7.2M$13.7M$6.4M
Stocks0000000000
Actifs Courants$37.3M$65.5M$195.7M$290.9M$703.1M$1.55B$1.24B$1.28B$1.07B$700.7M
Immobilisations Corporelles$633848$1.3M$3.6M$10.7M$14.3M$16.6M$17.8M$14.0M$16.0M$13.4M
Goodwill0000000000
Actifs Incorporels0000000000
Actifs Totaux$37.9M$66.8M$199.3M$301.6M$717.4M$1.58B$1.27B$1.30B$1.09B$717.9M
Dettes Fournisseurs$1.6M$596527$2.8M$4.6M$7.1M$31.3M$5.7M$17.8M$13.4M$24.4M
Dette à Court Terme$141212$159265$1544610000000
Passifs Courants$10.0M$17.9M$23.0M$32.8M$49.2M$261.7M$295.1M$257.1M$229.8M$142.5M
Dette à Long Terme$312575$151122$2.0M$2.0M$2.0M$1.0M$1.0M$800000$600000$400000
Passifs Totaux$13.9M$66.6M$62.6M$75.0M$75.2M$799.9M$703.9M$644.6M$529.7M$284.1M
Réserves-$33.8M-$62.4M-$302.3M-$372.6M-$491.9M-$682.9M-$965.4M-$1.33B-$1.53B-$1.61B
Capitaux Propres$24.0M$245870$136.7M$226.7M$642.2M$781.7M$564.9M$660.0M$561.7M$433.8M
Dette Totale$453787$310387$2.2M$4.4M$4.1M$5.0M$5.5M$3.2M$9.7M$8.9M
Dette Nette-$35.1M-$38.9M-$185.7M-$276.5M-$684.5M-$1.50B-$1.20B-$1.26B-$1.03B-$676.5M
Fonds de Roulement$27.2M$47.7M$172.7M$258.1M$653.9M$1.29B$945.1M$1.02B$837.5M$558.2M

Bilan (Trimestriel)

Année2025-Q32025-Q42026-Q12026-Q2
Trésorerie$101.5M$142.9M$87.3M$94.3M
Actifs Totaux$844.3M$717.9M$647.5M$675.1M
Passifs Totaux$279.9M$284.1M$260.7M$112.9M
Capitaux Propres$564.4M$433.8M$386.8M$562.2M
Dette Totale$9.5M$8.9M$8.4M$8.2M

Tableau de Flux (10 ans)

Année2016201720182019202020212022202320242025
Résultat Net-$14.4M-$24.0M-$41.5M-$70.3M-$119.3M-$191.0M-$282.5M-$367.3M-$198.9M-$80.8M
Amortissements$436329$347395$706000$2.3M$4.0M$6.0M$8.2M$6.7M$6.6M$5.2M
Stock-based Compensation$525586$245048$11.6M$20.1M$30.2M$57.1M$75.5M$71.6M$88.2M$44.0M
Variation du BFR-$5.6M$28.2M$12.6M$7.2M-$5.9M$678.3M-$82.6M-$44.4M-$140.6M-$233.7M
Cash Flow Opérationnel-$19.4M$5.1M-$16.1M-$40.6M-$89.8M$559.4M-$273.5M-$347.8M-$259.3M-$273.8M
CapEx-$306667-$1.0M-$2.8M-$6.2M-$6.4M-$4.7M-$6.8M-$2.9M-$1.8M-$1.9M
Acquisitions$5000000$86.8M-$395.1M0$4000000$1000000
Rachat d'Actions000000000-$91.9M
Dividendes Payés0000000000
Free Cash Flow-$19.7M$4.1M-$18.9M-$46.9M-$96.2M$554.7M-$280.3M-$350.7M-$261.1M-$275.7M

Tableau de Flux (Trimestriel)

Année2025-Q32025-Q42026-Q12026-Q2
Cash Flow Opérationnel-$59.1M-$30.4M-$69.2M-$48.3M
CapEx-$100000-$200000-$1.3M-$200000
Free Cash Flow-$59.2M-$30.6M-$70.5M-$48.5M
Dividendes Payés0000
Stock-based Compensation0$8.5M$11.4M$5.9M

Croissance et Marges (10 ans)

Année2016201720182019202020212022202320242025
Croissance Revenus (annuelle)+13.6%+89.0%+200.0%-39.7%+106.9%+145.1%-40.3%+235.5%-0.3%
Croissance Résultat Net (annuelle)-67.6%-72.5%-69.5%-69.7%-60.1%-47.9%-30.0%+45.8%+59.4%
Croissance BPA (annuelle)+81.7%+5.1%-44.3%-59.8%-26.5%-39.0%-24.7%+58.2%+53.8%
Variation Actions (annuelle)+992.6%+52.6%+4.1%+20.1%+26.5%+6.4%+4.3%+29.5%-9.7%
Croissance FCF (annuelle)+120.8%-562.1%-147.4%-105.3%+676.6%-150.5%-25.1%+25.5%-5.6%
Marge Brute100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%98.0%
Marge Opérationnelle-247.0%-326.7%-305.8%-119.9%-466.4%-351.5%-200.3%-511.5%-95.0%-43.8%
Marge EBITDA-208.9%-312.1%-284.3%-158.1%-454.1%-345.0%-192.8%-458.2%-72.8%-28.7%
Marge Nette-215.2%-317.3%-289.6%-163.6%-460.6%-356.3%-215.0%-467.9%-75.5%-30.8%
Marge FCF-295.5%54.1%-132.3%-109.1%-371.4%1034.9%-213.3%-446.8%-99.1%-105.0%
Taux d'Imposition Effectif0.6%-0.0%-0.0%-0.0%-0.0%-0.0%-8.0%-0.2%-0.3%-0.4%

Données par Action (10 ans)

Année2016201720182019202020212022202320242025
FCF par Action$-10.39$0.20$-0.60$-1.42$-2.43$11.09$-5.27$-6.32$-3.63$-4.25
Dividende par Action$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Actions en Circulation (Basiques)$1.9M$20.7M$31.6M$32.9M$39.5M$50.0M$53.2M$55.5M$71.9M$64.9M

Quoi regarder en Biotech

La plupart des petites biotechs perdent de l'argent. Les analyser avec le P/E n'a aucun sens — regardez cash et pipeline.

Rentabilité

Rentabilité des capitaux propres1.91%
Rentabilité du capital investi-2.18%
Rentabilité des actifs1.38%
Marge brute96.43%
Marge opérationnelle-4.45%
Marge nette2.94%

Santé financière

Dette / Capitaux propres0.01
Ratio de liquidité7.91
Piotroski F-Score4
Altman Z-Score-0.75

Ratios Clés (10 ans)

Année2016201720182019202020212022202320242025
PER-2.12-11.63-9.81-21.74-28.12-21.50-6.44-6.22-6.92-9.27
P/B1.271353.342.975.975.235.253.223.462.451.77
P/V4.5743.9028.3731.48129.6476.6213.8529.105.232.93
Marge Brute100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%98.0%
Marge Opérationnelle-247.0%-326.7%-305.8%-119.9%-466.4%-351.5%-200.3%-511.5%-95.0%-43.8%
Marge Nette-215.2%-317.3%-289.6%-163.6%-460.6%-356.3%-215.0%-467.9%-75.5%-30.8%

Entreprises liées: ATXS · AVBP · DAWN · DNA · ERAS · GERN · IOVA

Explorer le secteur: Healthcare · Biotechnology

Plus de sections de ARVN: Vue d'ensemble · Valorisation · Statistiques · Estimations · Technique · Actionnariat · Actualités · Événements

Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions